Japanese shareholders want to increase ownership in Ha Tay Pharmaceutical to 35%

Ha Tay Pharmaceutical announced that it has received a registration application to buy shares from ASKA Pharmaceutical, a Japanese shareholder, to increase its ownership ratio in the company to more than 35%.

Ha Tay Pharmaceutical Joint Stock Company (stock code: DHT) recently announced that it received a registration dossier for a public offering of 9,000 shares from ASKA Pharmaceutical Co., Ltd.

If successful, the largest shareholder at Ha Tay Pharmaceutical will increase its ownership ratio from 28.811 million shares (equivalent to 34.99%) to 28.820 million shares (equivalent to 35.001%). With a capital ownership ratio of over 35%, ASKA has the right to veto especially important decisions at this enterprise.

ASKA became a major shareholder at Ha Tay Pharmaceutical from the beginning of 2021 when this organization bought 5.28 million shares, increasing its ownership from 1.29 million shares (equivalent to 4.9% of charter capital) to 6.75 million shares (equivalent to 24.9% of charter capital).

At the end of 2023, ASKA continued to increase its ownership in Ha Tay Pharmaceutical to more than 26.8 million shares (equivalent to 32.56% of capital) after successfully collecting 8.4 million shares. In the first 2 months of this year, Japanese shareholders bought an additional 2 million DHT shares through transactions on the stock exchange, increasing the ownership ratio to 34.99%.

At the 2020 extraordinary general meeting of shareholders, Mr. Le Xuan Tham, member of the Board of Directors of Ha Tay Pharmaceutical, said that ASKA is the leading hormone-producing pharmaceutical company in Japan. Partnering with ASKA will bring many advantages to Ha Tay Pharmaceutical because the partner is also a top 17 pharmaceutical manufacturer in Japan and has 4 factories, one of which has met Japanese PIC/S standards. In addition, ASKA is committed to supporting the company in designing, training, instructing, guiding operations, connecting and evaluating... a high-tech pharmaceutical factory for Ha Tay Pharmaceutical.

On the stock exchange, DHT shares are currently at 69,300 VND/share, down more than 6% compared to the historical peak set in the session on July 17 (74,000 VND). The average matched volume of shares in the last 10 sessions is more than 34,000 units. With more than 82.3 million shares in circulation, the market capitalization is more than 5,706 billion VND.

According to the audited financial report, Ha Tay Pharmaceutical achieved net revenue in the first half of the year of more than VND999 billion, a slight decrease compared to VND1,046 billion in the same period. Gross profit was approximately VND101 billion, with a profit margin of more than 10%.

After deducting expenses, the company reported pre-tax profit of VND42.7 billion and after-tax profit of about VND34.6 billion, both down more than 35% compared to the same period last year.

This year, Duoc Ha Tay plans to have total revenue of 1,769 billion VND, down 147 billion VND compared to the actual figure in 2023. Pre-tax profit of 78.5 billion VND, down 20 billion VND compared to the same period. The Board of Directors said that Duoc Ha Tay is aiming to be in the top 2 domestic pharmaceutical companies with the largest revenue and profit this year. After half a year, the company has completed 56.5% of the revenue plan and 54.4% of the profit target.

The company's total assets as of the end of June were over VND1,765 billion, a slight decrease compared to VND1,838 billion at the beginning of the period. Liabilities were over VND709 billion, most of which were short-term debts. Equity decreased slightly compared to the beginning of the year, reaching VND1,056 billion. Undistributed profit after tax was about VND81.2 billion.

Source: https://baodautu.vn/co-dong-nhat-ban-muon-nang-so-huu-tai-duoc-ha-tay-len-35-d223705.html